Shares of Novartis (NOVN: VX) were up 2.09% at 75.65 Swiss francs by 9.40 this morning, after the Swiss pharma giant posted first-quarter 2017 financial results with both sales and profits down year-on-year.
Net sales for the quarter were $11.5 billion (-1%, +2% constant exchange), as volume growth of 7 percentage points was partially offset by the negative impact of generic competition (-3 percentage points) and pricing (-2 percentage points).
This missed the estimates of analysts polled by Bloomberg, who expected $11.6 billion. All divisions reported growth in constant currencies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze